Vascular Lesions Treatment (Target Creation Technology®)

Target Creation Technology® (TCT) is LINLINE’s transcutaneous method for treating dilated vessels—from facial telangiectasias and hemangiomas to leg spider veins—on the MULTILINE™ base unit with the Nd:YAP/KTP 1079/540 nm Q-switched emitter. TCT uses a two-wavelength, pulse-train sequence to build a selective “target” inside the vessel and then complete coagulation—while protecting the surrounding skin. 

Why TCT is different

• Selectivity by design. Lasers can’t choose hemoglobin over melanin reliably by wavelength alone. TCT solves this by creating a new intravascular chromophore (the “target”) and then heating only that target, so energy goes to the vessel—not to other skin chromophores.
• Three actions in one sequence.
  1. Eliminate “false targets” — a gentle 1079 nm pre-pass creates slight tumescence that compresses superficial capillaries, reducing competitive hemoglobin.
  2. Create the target — 540 nm Q-sw pulses coagulate a thin blood layer at the vessel wall, forming a high-absorption “new chromophore.”
  3. Destroy the dilated vessel — 1079 nm Q-sw pulses now couple to the new chromophore and coagulate the whole lumen with minimal collateral heat.
• What you see on table. The correct endpoint is visible darkening of the vessel. Instant disappearance usually means blood was squeezed out, not coagulated. Frosting/whitening of the skin is a sign of excess energy and should be avoided.
• Skin-friendly workflow. The method has been used without routine skin cooling and with no scarring reported when parameters are respected.

What a session is like

• Sensation: a brief, warm tingling; cold air can be used for comfort.
• Immediately after: treated vessels look darker; surrounding skin may show mild redness for hours and light swelling (up to 24 h peri-orbital).
• Aftercare: avoid rubbing/trauma; no saunas/steam/hot baths for 7 days. Avoid direct sun/solarium for 14 days and use SPF to limit PIH risk. 

Practitioner essentials

• Emitter & wavelengths: Nd:YAP/KTP (1079/540 nm), Q-switched pulse trains on MULTILINE™.
• Pulse logic: Pre-tumescence at 1079 nm → target formation at 540 nm → target-selective coagulation at 1079 nm. Multiphoton threshold and inter-pulse gaps are tuned to minimize melanin load. 

Indications & areas

• Facial telangiectasias, rosacea networks, hemangiomas.
• Leg spider veins (telangiectasias/reticular).
• Not for varicose vein disease: treat surgically/endovenously first; TCT can address residual telangiectasias after.

Safety & contraindications

• Tanned skin caution: melanin competes with hemoglobin; raising energy to “push through” increases PIH/complication risk—better to time/adjust correctly and follow sun restrictions.
• Do not stack pulses on the same spot and don’t exceed the recommended frequency (≤ 3 Hz face/hemangiomas; ≈ 1 Hz legs). Excess heat raises complication risk without improving coagulation.
• Endpoint discipline: darkening yes; frosting no. 

How TCT compares

Benefits at a glance

For patients

• Effective on a wide range of vessels (face & body) with minimal skin trauma.
• Natural skin tone preserved; protocol and sun care minimize PIH risk.
• Comfortable: warm tingling; quick return to routine.

For practitioners

• True selectivity via target creation—not wavelength alone.
• Clear, reproducible endpoints (darkening) and program-guided frequency.
• Platform simplicity: run TCT on the MULTILINE™ base unit with the Nd:YAP/KTP 1079/540 nm emitter; stable output and presets support consistent results. 

Key takeaway

TCT treats vascular lesions by building a selective target inside the vessel and then coagulating it—delivering results across many vessel sizes with skin-sparing precision, clear endpoints, and a platform workflow clinicians can standardize.